Adult pilocytic astrocytomas: clinical features and molecular analysis

Neuro Oncol. 2014 Jun;16(6):841-7. doi: 10.1093/neuonc/not246. Epub 2014 Jan 26.

Abstract

Background: Adult pilocytic astrocytomas (PAs) are rare and have an aggressive clinical course compared with pediatric patients. Constitutive Ras/RAF/MAPK signaling appears to be an important oncogenic event in sporadic PA. We evaluated clinical data and molecular profiles of adult PAs at our institution.

Methods: We identified 127 adult PAs in our institutional database. Cases with available tissue were tested for BRAF-KIAA1549 fusion/duplication (B-K fusion) by fluorescence in situ hybridization and submitted for mutation profiling using the Sequenom mutation profiling panel. Subgroup analyses were performed based on clinical and molecular data.

Results: The majority of adult PAs are supratentorial. Twenty-two percent of cases had an initial pathologic diagnosis discordant with the diagnosis made at our institution. Recurrence was seen in 42% of cases, and 13% of patients died during follow-up. Adjuvant radiotherapy following surgical resection was associated with a statistically significant decrease in progression-free survival (P = .004). B-K fusion was identified in 20% (9 of 45) of patients but was not associated with outcome. No BRAF V600E mutations (0 of 40 tested) were found.

Conclusion: This was the largest single institution series of adult PA. A significant proportion of adult PAs follow an aggressive clinical course. Our results support a period of observation following biopsy or surgical resection. B-K fusion in adult PA does not influence outcome, and BRAF V600E mutation appears to be a very rare event. Further study of tumor biology and optimal treatment is needed, given a more aggressive clinical behavior.

Keywords: BRAF mutation; low-grade astrocytoma; pilocytic astrocytoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Astrocytoma / diagnosis*
  • Astrocytoma / genetics
  • Brain Neoplasms / diagnosis*
  • Brain Neoplasms / genetics
  • Female
  • Humans
  • Male
  • Middle Aged
  • Mutation
  • Oncogene Proteins, Fusion / genetics
  • Treatment Outcome
  • Young Adult

Substances

  • BRAF-KIAA1549 fusion protein, human
  • Oncogene Proteins, Fusion